Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + epacadostat versus pembrolizumab + placebo as first-line treatment for metastatic PD-L1-high non-small cell lung cancer
MOH_2017-11-26_001973Phase 3Completed
- Sponsor
- Incyte
- Start
- Nov 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and epacadostat in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Incyte. Started Nov 2017; status: completed.
02
Drugs
pembrolizumabepacadostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2017-11-26_001973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-26_001973.